Dipeptidyl peptidase-4 (DPP-4) inhibitors, which have been widely used as outstanding blood glucose-dependent antidiabetic agents for patients with type 2 diabetes mellitus (T2DM), show promise. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.